STOCK TITAN

Neurocrine Biosciences director Lyons sells 15,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Neurocrine Biosciences Inc. director Gary A. Lyons exercised 15,000 non-qualified stock options at $53.64 per share, acquiring 15,000 common shares on November 17, 2026. He sold 15,000 common shares that day in four sale entries, with the dispositions effected by a broker under a Rule 10b5-1 trading plan.

Insider LYONS GARY A
Role Director
Sold 15,000 shs ($2.47M)
Approx. gross sale proceeds $2.47M
Approx. exercise cost $805K
Approx. pre-tax spread $1.67M
Type Security Shares Price Value
Exercise Non-Qualified Stock Option F7 15,000 $0.00 $0.00
Exercise Common Stock 15,000 $53.64 $805K
Sale Common Stock F1, F2 1,200 $163.1106 $196K
Sale Common Stock F1, F3 4,011 $163.938 $658K
Sale Common Stock F1, F4 5,689 $165.1547 $940K
Sale Common Stock F1, F5, F6 4,100 $165.8968 $680K
Holdings After Transaction: Non-Qualified Stock Option — 0 options (Direct); Common Stock — 122,141 shares (Direct)
Footnotes (7)
  1. F1. The dispositions reported in this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  2. F2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $162.45 to $163.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. F3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.49 to $164.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. F4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.57 to $165.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. F5. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.57 to $166.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  6. F6. 116,158 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.
  7. F7. The option was granted May 22, 2017 and vested in 12 equal monthly installments beginning June 22, 2017. These options are due to expire on May 22, 2027.
Non-qualified stock options exercised 15,000 options November 17, 2026
Option exercise price $53.64 per share November 17, 2026
Common shares acquired upon exercise 15,000 shares November 17, 2026
Common shares sold 15,000 shares November 17, 2026, across four sale entries
Weighted-average sale price (1,200 shares) $163.1106 per share November 17, 2026
Weighted-average sale price (4,011 shares) $163.9380 per share November 17, 2026
Weighted-average sale price (5,689 shares) $165.1547 per share November 17, 2026
Weighted-average sale price (4,100 shares) $165.8968 per share November 17, 2026
Non-Qualified Stock Option financial
"exercised 15,000 non-qualified stock options"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Rule 10b5-1 trading plan regulatory
"under instructions set forth in a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price per share financial
"Represents a weighted average sales price per share"
vested in 12 equal monthly installments financial
"vested in 12 equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NBIX shares did Gary A. Lyons sell?

Gary A. Lyons sold 15,000 common shares on November 17, 2026, across four sale entries. Their weighted-average prices were $163.1106, $163.9380, $165.1547 and $165.8968 per share.

How many NBIX options did Gary A. Lyons exercise?

He exercised 15,000 non-qualified stock options at $53.64 per share, acquiring 15,000 common shares on November 17, 2026.

When was the trading plan used for Gary A. Lyons’s NBIX sale adopted?

The Rule 10b5-1 trading plan was adopted on August 18, 2026. The dispositions were effected by a broker under instructions in the plan, and issuer policy restricts the reporting person from amending or otherwise modifying a plan after adoption.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LYONS GARY A

(Last)(First)(Middle)
6027 EDGEWOOD BEND CT.

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026M15,000A$53.64137,141D
Common Stock11/17/2026S(1)1,200D$163.1106(2)135,941D
Common Stock11/17/2026S(1)4,011D$163.938(3)131,930D
Common Stock11/17/2026S(1)5,689D$165.1547(4)126,241D
Common Stock11/17/2026S(1)4,100D$165.8968(5)122,141D(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option$53.6411/17/2026M15,000 (7)05/22/2027Common Stock15,000$00D
Explanation of Responses:
1. The dispositions reported in this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $162.45 to $163.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.49 to $164.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.57 to $165.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
5. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.57 to $166.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
6. 116,158 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.
7. The option was granted May 22, 2017 and vested in 12 equal monthly installments beginning June 22, 2017. These options are due to expire on May 22, 2027.
Remarks:
/s/ Darin Lippoldt, Attorney-in-Fact11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading